bioMerieux


Another quarter of double-digit growth; full-year targets exceeded

25/02/21 -"Benefitting from sustained demand for COVID-19 testing solutions, bioMerieux reported another quarter of double-digit growth in Q4 20. Interestingly, the FY20 targets were exceeded, both on the sales ..."

Pages
53
Language
English
Published on
25/02/21
You may also be interested by these reports :
13/04/21
Our target price upgrade is largely attributable to the higher DCF valuation, which now acknowledges the faster-than-expected and more profitable ...

02/04/21
Hearing aid specialist Demant (Reduce, Denmark) was recovering from its cyberattack woes when we last teased about it in November 2019. ...

30/03/21
COVID-19 continues to be mixed bag for GN. Audio has got off to a solid start in 2021, though Hearing is still a drag – extended lockdowns weighed on ...

26/03/21
Our target price upgrade is largely attributable to the higher DCF valuation, which now acknowledges the faster-than-expected and more profitable ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO